1,3-dibenzyl-5-methyl-2-(trimethylsilyl)-1,2-dihydropyridine 在
palladium on activated charcoal air 、 氢气 作用下,
以
2,2,2-三氟乙醇 、 甲苯 为溶剂,
反应 28.0h,
以65 mg的产率得到3-甲基-5-(苯基甲基)吡啶
参考文献:
名称:
Synthesis of Dihydropyridines and Pyridines from Imines and Alkynes via C−H Activation
摘要:
A convenient one-pot C-H alkenylation/electrocyclization/aromatization sequence has been developed for the synthesis of highly substituted pyridine derivatives from alkynes and alpha,beta-unsaturated N-benzyl aldimines and ketimines that proceeds through dihydropyridine intermediates. A new class of ligands for C-H activation was developed, providing broader scope for the alkenylation step than could be achieved with previously reported ligands. Substantial information was obtained about the mechanism of the reaction. This included the isolation of a C-H activated complex and its structure determination by X-ray analysis; in addition, kinetic simulations using the Copasi software were employed to determine rate constants for this transformation, implicating facile C-H oxidative addition and slow reductive elimination steps.
Regioselectively Functionalized Pyridines from Sustainable Resources
作者:Stefan Michlik、Rhett Kempe
DOI:10.1002/anie.201301919
日期:2013.6.10
Ir‐catalyzed dehydrogenative condensation of alcohols and 1,3‐amino alcohol was used to construct pyridine derivatives regioselectively. This method provides access to unsymmetrically substituted pyridines and tolerates a wide variety of functional groups. Three equivalents of H2 are generated per pyridine unit formed and the alcohol substrates become completely deoxygenated.
A new method for the alkyl group introduction at the 3-position of pyridienes is described: Reductive disilylation of pyridine, its 2-methyl, 3-methyl, and 4-methyl derivatives affords the corresponding 1,4-disilyl-1,4-dihydropyridines. In the presence of a catalytic amount of tetrabutylammonium fluoride, these dihydropyridines smoothly react with a variety of aldehydes and ketones to give 3-alkylpyridines
ASK1 inhibitor and preparation method and use thereof
申请人:FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.
公开号:US10787435B2
公开(公告)日:2020-09-29
The present disclosure relates to a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.